This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07630168

Phase 1

Phase I Decitabine Dose-Tolerance in Surgically Resectable HPV-Negative Head and Neck Cancer

This phase I trial tests the safety, side effects, and best dose of decitabine in combination with standard of care surgery, radiation, and/or chemotherapy and…

Human Papillomavirus-Negative Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaResectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma+2 more

~Estimated

~$10 – $6,250

Mayo ClinicNCT06997094